DATED [●] (2) A.T. DEVELOPMENT SWITZERLAND SARL AND (3) ADC THERAPEUTICS SARLPurchase and Shareholders Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • England and Wales
Amendment# 1 to the Second Amended and Restated License Agreement dated May 9, 2016License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
This Amendment# 1 (“Amendment #1”) dated 19 September 2018 (“Amendment Effective Date”) is made by and between ADC Products (UK) Ltd., with registered address at registered office is at 4th Floor, Reading Bridge House, George Street, Reading, Berkshire RG l 8LS, United Kingdom (“ADCP”), ADC Therapeutics SA, with registered address at Route de la Corniche 3B, 1066 Epalinges, Switzerland (“ADCT”), and Medimmune Ltd., with registered office at Milstein Building, Granta Park, Cambridge CB21 6GH (“Medlmmune”), each hereinafter individually referred to as “Party” and jointly as “Parties”.
womblebonddickinson.comLease • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
Building the Queen Mary Bioenterprises Innovation Centre 42 New Road Whitechapel E1 2AX being all the land comprised in Title Number EGL520546.
Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/SCollaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York
This Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of 14 June 2013 (“Effective Date”), by and between ADC Therapeutics Sarl, a Swiss corporation, having its head office at Rue Saint-Pierre 2, Lausanne, 1003, Switzerland (“ADCT”), and Genmab A/S, a Danish corporation, having its principal place of business at [**] (“Genmab”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT to COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
This Amendment to the Collaboration and License Agreement dated 14 June 2013 between Genmab A/S (“Genmab”) and ADC Therapeutics Sarl (“ADCT”) (hereinafter referred to as the “Agreement”) is entered into with effect from 20 November 2013 by and between Genmab and ADCT (together referred to as “Parties”). All capitalized terms below are as defined in the Agreement.
FORM OF INDEMNITY AGREEMENTIndemnification Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC Therapeutics...License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
This Second Amended and Restated License Agreement (“Agreement”) is made and entered into as of May 9, 2016 (“Execution Date”), by and among:
SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT BETWEEN ADC THERAPEUTICS SA AND GENMAB A/SCollaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
